Trust facts

Important Information

We want to make investing with us simple and straightforward for all of our clients.

Please select your investor type from the options below.

Alternatively you can register or log in to an existing account.

Please note that by making your selection here you are agreeing to the Woodford Investment Management Ltd Privacy Statement and to our Terms and Conditions.

Woodford Patient Capital Trust plc

As at 28 February 2017

Trust nameWoodford Patient Capital Trust plc
Investment managerWoodford Investment Management Ltd
Investment objectiveTo achieve long-term capital growth through investing in a portfolio consisting predominantly of UK companies, both quoted and unquoted. The Company will aim to deliver a return in excess of 10% per annum over the longer term. (Note: this is a target only and not a profit forecast and there can be no assurance that it will be met.)
Independent board directorsSusan Searle (Chair)
Scott Brown
Steven Harris
Dame Pamela Louise Makin
Alan Hodson
Carolan Dobson
Total assets (GBP)£814.7m

Latest trust update

Patient Capital Trust update, February 2017

Mitchell Fraser-Jones 17 March 2017 7 min read

Taking a look back at how the Woodford Patient Capital Fund delivered a positive return in February, and discover our future predictions for Atom Bank.

Read more

Performance since launch

Performance summary
 1 month3 monthsYear-to-date1 yearSince launch
(21st April 2015)
Net asset value3.615.354.4411.18-2.08
Ordinary share price1.682.462.806.13-6.45
Standardised performance (%)
 01/01/12 to
31/12/12
01/01/13 to
31/12/13
01/01/14 to
31/12/14
01/01/15 to
31/12/15
01/01/16 to
31/12/16
Net asset value-----3.53
Ordinary share price-----9.90

Past performance cannot be relied upon as a guide to future performance.
Source: Morningstar Direct on a total return basis, with net income reinvested.

Portfolio analysis

Top 10 holdings
NameIndustryWeight (%)
ProthenaHealth Care16.27
PurplebricksFinancials7.73
Oxford Nanopore (unquoted)Health Care7.37
Immunocore A (unquoted)Health Care5.37
Theravance BiopharmaHealth Care4.78
Proton Partners International (unquoted)Health Care4.22
Mereo BiopharmaHealth Care3.92
Oxford Sciences Innovation (unquoted)Financials3.38
Allied MindsFinancials3.16
4D PharmaHealth Care2.87
Total (of top 10) 59.07

View the full portfolio

Performance contribution – 1 year to 31 December 2016

Sector allocation
IndustryWeight (%)
Health Care66.29
Financials30.01
Industrials7.31
Technology5.60
Telecommunications1.79
Consumer Goods0.67
Basic Materials0.37
Cash and near cash-12.04
Total100.00
Geographical allocation
CountryFund (%)
United Kingdom81.04
United States24.67
Norway3.07
Ireland1.67
Switzerland1.00
Luxembourg0.59
Maturity breakdown
Maturity stageWeight (%)
Mid/large cap23.99
Early growth39.93
Early stage48.12
Listing statusWeight (%)
Quoted65.54
Unquoted46.50

Prices and fees

Month-end prices As at 28 February 2017
 Price (p)
Market share price93.55p
Net asset value (Ex Income)97.92p
Net asset value (Cum Income)97.92p

View daily prices

Fees
Annual management feeNone
Performance fee15% of any excess returns over a 10% cumulative hurdle rate per annum, subject to a high watermark
Ongoing annual expenses0.1%

    By using this website you are automatically agreeing to the Woodford Investment Management Ltd privacy statement